The company said the dossier submission is to support the FSA’s move to regulate the currently unregulated CBD market in the UK.
“It’s been a huge pleasure to spend the past few months leading a dedicated team to compile a robust evidence-based dossier for submission to the FSA. To my knowledge, Love Hemp’s application is also in the unique position of having provided comprehensive pre-clinical results, based on our own proprietary study protocols, investigating the effects of Love Hemp’s finished product formulations on the pharmacokinetics of CBD. To have been able to do this at pre-validation stage is a great achievement,” Love Hemp’s chief scientific and regulatory affairs lead Sepe Sehati said in a statement.
“We are committed to providing our consumers with the highest quality THC-free CBD products and believe the new Novel Food regulations will help end regulatory uncertainty surrounding CBD in the UK,” added World High Life and Love Hemp chief executive Tony Calamita.